PHARMING GROUP NV - ADR (PHAR) Stock Fundamental Analysis
NASDAQ:PHAR - Nasdaq - US71716E1055 - ADR - Currency: USD
Taking everything into account, PHAR scores 4 out of 10 in our fundamental rating. PHAR was compared to 550 industry peers in the Biotechnology industry. PHAR has an average financial health and profitability rating. PHAR is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
PHAR had negative earnings in the past year.
In the past year PHAR had a positive cash flow from operations.
In multiple years PHAR reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: PHAR reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of -3.50%, PHAR belongs to the top of the industry, outperforming 88.00% of the companies in the same industry.
The Return On Equity of PHAR (-6.59%) is better than 89.09% of its industry peers.
Looking at the Return On Invested Capital, with a value of 2.05%, PHAR belongs to the top of the industry, outperforming 91.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.5% | ||
| ROE | -6.59% | ||
| ROIC | 2.05% |
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Operating Margin value of 2.63%, PHAR belongs to the best of the industry, outperforming 92.00% of the companies in the same industry.
The Gross Margin of PHAR (88.98%) is better than 91.27% of its industry peers.
PHAR's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.63% | ||
| PM (TTM) | N/A | ||
| GM | 88.98% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PHAR is destroying value.
The number of shares outstanding for PHAR has been increased compared to 1 year ago.
Compared to 5 years ago, PHAR has more shares outstanding
The debt/assets ratio for PHAR has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.72 indicates that PHAR is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.72, PHAR is doing good in the industry, outperforming 71.82% of the companies in the same industry.
PHAR has a debt to FCF ratio of 23.45. This is a negative value and a sign of low solvency as PHAR would need 23.45 years to pay back of all of its debts.
PHAR's Debt to FCF ratio of 23.45 is amongst the best of the industry. PHAR outperforms 91.45% of its industry peers.
A Debt/Equity ratio of 0.52 indicates that PHAR is somewhat dependend on debt financing.
PHAR has a worse Debt to Equity ratio (0.52) than 74.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 23.45 | ||
| Altman-Z | 2.72 |
ROIC/WACC0.3
WACC6.74%
2.3 Liquidity
PHAR has a Current Ratio of 2.76. This indicates that PHAR is financially healthy and has no problem in meeting its short term obligations.
PHAR's Current ratio of 2.76 is on the low side compared to the rest of the industry. PHAR is outperformed by 67.45% of its industry peers.
PHAR has a Quick Ratio of 2.00. This is a normal value and indicates that PHAR is financially healthy and should not expect problems in meeting its short term obligations.
PHAR's Quick ratio of 2.00 is on the low side compared to the rest of the industry. PHAR is outperformed by 73.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.76 | ||
| Quick Ratio | 2 |
3. Growth
3.1 Past
PHAR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.00%, which is quite impressive.
PHAR shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.15%.
PHAR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.64% yearly.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%175%
Revenue 1Y (TTM)21.15%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%25.79%
3.2 Future
The Earnings Per Share is expected to grow by 52.28% on average over the next years. This is a very strong growth
PHAR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.99% yearly.
EPS Next Y183.09%
EPS Next 2Y10.31%
EPS Next 3Y46.06%
EPS Next 5Y52.28%
Revenue Next Year13.88%
Revenue Next 2Y11.18%
Revenue Next 3Y10.03%
Revenue Next 5Y9.99%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PHAR. In the last year negative earnings were reported.
Also next year PHAR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PHAR is valued cheaper than 92.18% of the companies in the same industry.
91.64% of the companies in the same industry are more expensive than PHAR, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 153.21 | ||
| EV/EBITDA | 34.66 |
4.3 Compensation for Growth
A more expensive valuation may be justified as PHAR's earnings are expected to grow with 46.06% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.31%
EPS Next 3Y46.06%
5. Dividend
5.1 Amount
No dividends for PHAR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:PHAR (8/14/2025, 4:30:01 PM)
11.38
+0.13 (+1.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners10.96%
Inst Owner Change8.14%
Ins Owners1.41%
Ins Owner ChangeN/A
Market Cap778.31M
Analysts88.57
Price Target18.5 (62.57%)
Short Float %0%
Short Ratio0.27
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-34.81%
Min EPS beat(2)-42.39%
Max EPS beat(2)-27.22%
EPS beat(4)1
Avg EPS beat(4)-61.09%
Min EPS beat(4)-197.09%
Max EPS beat(4)22.33%
EPS beat(8)3
Avg EPS beat(8)-66.01%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)12.4%
Min Revenue beat(2)11.43%
Max Revenue beat(2)13.37%
Revenue beat(4)2
Avg Revenue beat(4)3.98%
Min Revenue beat(4)-5.54%
Max Revenue beat(4)13.37%
Revenue beat(8)5
Avg Revenue beat(8)1.21%
Revenue beat(12)5
Avg Revenue beat(12)-2.03%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.03%
PT rev (3m)17.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-227.56%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.73%
Revenue NQ rev (1m)0.76%
Revenue NQ rev (3m)5.47%
Revenue NY rev (1m)-0.38%
Revenue NY rev (3m)-0.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.43 | ||
| P/FCF | 153.21 | ||
| P/OCF | 127.93 | ||
| P/B | 3.64 | ||
| P/tB | 10.36 | ||
| EV/EBITDA | 34.66 |
EPS(TTM)-0.13
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)0.07
FCFY0.65%
OCF(TTM)0.09
OCFY0.78%
SpS4.69
BVpS3.13
TBVpS1.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.5% | ||
| ROE | -6.59% | ||
| ROCE | 2.59% | ||
| ROIC | 2.05% | ||
| ROICexc | 3.06% | ||
| ROICexgc | 8.39% | ||
| OM | 2.63% | ||
| PM (TTM) | N/A | ||
| GM | 88.98% | ||
| FCFM | 1.58% |
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
F-Score5
Asset Turnover0.8
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 23.45 | ||
| Debt/EBITDA | 5.21 | ||
| Cap/Depr | 7.89% | ||
| Cap/Sales | 0.31% | ||
| Interest Coverage | 2.2 | ||
| Cash Conversion | 28.73% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.76 | ||
| Quick Ratio | 2 | ||
| Altman-Z | 2.72 |
F-Score5
WACC6.74%
ROIC/WACC0.3
Cap/Depr(3y)9.71%
Cap/Depr(5y)59.68%
Cap/Sales(3y)0.61%
Cap/Sales(5y)3.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%175%
EPS Next Y183.09%
EPS Next 2Y10.31%
EPS Next 3Y46.06%
EPS Next 5Y52.28%
Revenue 1Y (TTM)21.15%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%25.79%
Revenue Next Year13.88%
Revenue Next 2Y11.18%
Revenue Next 3Y10.03%
Revenue Next 5Y9.99%
EBIT growth 1Y128.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year21.21%
EBIT Next 3Y76.77%
EBIT Next 5Y85.48%
FCF growth 1Y284.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y750%
OCF growth 3YN/A
OCF growth 5YN/A